CTOs on the Move


 
Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pieris.com
  • 255 State Street 9th floor
    Boston, MA USA 02109
  • Phone: 857.246.8998

Executives

Name Title Contact Details

Funding

Pieris raised $50.6M on 02/20/2018
Pieris raised $32M on 11/10/2019
Pieris raised $17.3M on 06/25/2021
Pieris raised $25M on 07/05/2021

Similar Companies

4D Pharmacy Management Systems Inc

4D Pharmacy Management Systems Inc is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Total Care Rx

Total Care RX serves as an extension of the patient’s medical team to monitor medication compliance, provide education and offer other value-added services not offered by retail pharmacies.

Talia Technology (Marco Ophthalmic)

Talia Technology (Marco Ophthalmic Inc.) is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TFF Pharmaceuticals

TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions.

Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: TREXIMET®, SILENOR®, a non-narcotic product indicated for the treatment of insomnia characterized by difficulties with sleep maintenance, KHEDEZLA™, as well as CEDAX®, an antibiotic for middle ear infections. The Company promotes its branded products to physicians through its Pernix sales force and distributes its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is based in Morristown, New Jersey.